Literature DB >> 27642088

miR-218 Inhibits Proliferation, Migration, and EMT of Gastric Cancer Cells by Targeting WASF3.

Guojun Wang, Yang Fu, Guanghui Liu, Yanwei Ye, Xiefu Zhang.   

Abstract

MicroRNAs (miRNAs) play an important role in carcinogenesis. miR-218 is one of the most known miRNAs and has been demonstrated to inhibit progression in gastric cancer. However, the underlying molecular mechanism is not established. In this study, qRT-PCR and Western blot indicated that miR-218 was downregulated in gastric cancer cell lines SGC7901 and BGC823 compared to that in normal gastric epithelial cell line GES-1. MTT and wound scratch assays suggested that overexpression of miR-218 markedly suppressed cell proliferation, migration, and EMT of gastric cancer cells. Furthermore, we proved that WASF3 was a direct target of miR-218 by luciferase reporter assay, and restoration of WASF3 expression impairs miR-218-induced inhibition of proliferation, migration, and EMT in gastric cancer cells SGC7901. In summary, our results demonstrated that miR-218 functions as one of the tumor-suppressive miRNAs and inhibits gastric cancer tumorigenesis by targeting WASF3. miR-218 may serve as a potential therapeutic target for the treatment of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27642088     DOI: 10.3727/096504016X14738114257367

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  23 in total

1.  MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma.

Authors:  Shanshan Li; Chengqun Luo; Jun Zhou; Yong Zhang
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

2.  In Silico Optimized Stapled Peptides Targeting WASF3 in Breast Cancer.

Authors:  Ameya J Limaye; George N Bendzunas; Matthew K Whittaker; Timothy J LeClair; Leah G Helton; Eileen J Kennedy
Journal:  ACS Med Chem Lett       Date:  2022-03-08       Impact factor: 4.632

3.  Nicotinamide N-methyltransferase promotes epithelial-mesenchymal transition in gastric cancer cells by activating transforming growth factor-β1 expression.

Authors:  Liang Liang; Ming Zeng; Haixia Pan; Hao Liu; Yangke He
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

4.  MicroRNA-218 inhibits the migration, epithelial-mesenchymal transition and cancer stem cell properties of prostate cancer cells.

Authors:  Bing Guan; Lijun Mu; Linlin Zhang; Ke Wang; Juanhua Tian; Shan Xu; Xinyang Wang; Dalin He; Yuefeng Du
Journal:  Oncol Lett       Date:  2018-06-01       Impact factor: 2.967

5.  MicroRNA-599 suppresses glioma progression by targeting RAB27B.

Authors:  Yu Jiang; Xiaohui Wang; Ji Zhang; Renchun Lai
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

6.  Methylation-induced downregulation and tumor suppressive role of microRNA-29b in gastric cancer through targeting LASP1.

Authors:  Hui Li; Guoqing Liu; Ke Pan; Xiongying Miao; Yong Xie
Journal:  Oncotarget       Date:  2017-09-30

7.  MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.

Authors:  Juhua Zhuang; Ying Ye; Guoyu Wang; Jing Ni; Saifei He; Cuihua Hu; Wei Xia; Zhongwei Lv
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 3.423

8.  miR-663b promotes tumor cell proliferation, migration and invasion in nasopharyngeal carcinoma through targeting TUSC2.

Authors:  Shaoqiang Liang; Ning Zhang; Yanming Deng; Lusi Chen; Yang Zhang; Zhenhe Zheng; Weijun Luo; Zhiqian Lv; Shaoen Li; Tao Xu
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

9.  microRNA-23a promotes cell growth and metastasis in gastric cancer via targeting SPRY2-mediated ERK signaling.

Authors:  Yingjia Li; Hui Chen; Pengfei She; Ti Chen; Lihua Chen; Jinling Yuan; Botao Jiang
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

10.  miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican.

Authors:  Ping Yang; Pingyuan Bu; Chengyuan Li
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.